Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director

November 01, 2024 06:28 PM AEDT | By Cision

Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director — Image source: Kalkine Media

Recent News

Spin, Win, Repeat: Bybit Daily Delight Keeps Users Engaged with 600,00...

G-P Welcomes Tech Veteran Rohit Bedi as Chief Revenue Officer

Reckitt, Abbott surge after winning an NEC case

The third edition of The MICHELIN Guide Abu Dhabi is unveiled

TAIPEI and SAN DIEGO, Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr. Yiu-Lian Fong to the board of directors for Ding Li Development Ltd. Dr. Fong, a present member of the Bio Taiwan Committee (BTC) under the Executive Yuan since 2020, has served various organizations in Taiwan including the BTC, the Ministry of Science and Technology Council, and the Medical Device Innovation Center, NCKU as an expert consultant since 2017 to help drive the growth of Biotech industry. Dr. Fong previously served as the Global Head, Diagnostic Innovation and R&D and Clinical Biomarker Strategy and Development at Janssen, Johnson & Johnson. Having nearly thirty years of successful R&D leadership experience for new drug discovery and development in the global pharmaceutical companies, Dr. Fong is dedicated to addressing unmet medical needs for major diseases such as cancer. Her versatile experiences will provide valuable insights into Senhwa's strategic approaches to developing new drugs, help accelerate development timelines, and position Senhwa for the global market.

Dr. Fong received her PhD at Vanderbilt University and completed her post-doctoral training at the Johns Hopkins University. She held important and progressive leadership positions in various global pharmaceutical and IVD companies. She advanced from scientist to the Director of R&D for Novartis Vaccine and Drug Development, and subsequently to the Executive Director at the Novartis Molecular Diagnostics and the Novartis Oncology Division for Drug and Companion Diagnostic co-development. Following her role as Vice President of R&D in Abbott's Molecular Diagnostic Division, she joined Janssen Pharmaceuticals to assume global R&D leadership roles including the Global Head of Diagnostic Innovation, R&D, and CLIA Lab Operation, and the Global Head of Clinical Biomarker and Diagnostic Strategy and Development to help drive the development of precision medicines. Over her 28-year career, Dr. Fong has not only successfully led/directed numerous important R&D programs from pre-clinical, phase I-III to regulatory approval, but also supported phase-IV post-approval studies to accelerate global market expansions. Furthermore, Dr. Fong has demonstrated her expertise in strategic planning for global partnerships and global market penetration for pharmaceuticals and IVD (companion) diagnostics. Her professional expertise and experience in the biotech/pharma/IVD industry will contribute significantly to Senhwa's efforts in progressing the R&D pipeline, and facilitate the global partnerships and commercial success.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Full Name

Mobile

By submitting your details above and clicking on the 'Download Report' button, you confirm that you are happy for one of the representatives of Kalkine Media or its group entities to contact you to discuss the services, consent to - our Terms & Conditions, and to receive marketing offers, including to be contacted by email or phone, as set out in our Privacy Policy. Any calls will be made by Kalkine group's telemarketing entities on our behalf or on behalf of Kalkine group entities.